ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 9

A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation

Vinicius Domingues1, Darshana Dadhania2, Choli Hartono2, Raymond Pastore3 and Doruk Erkan4, 11320 York Avenue 17n, New York Presbyterian Hospital, New York, NY, 2Nephrology and Hypertension, New York Presbyterian Hospital, new york, NY, 3Hematology and Oncology, New York Presbyterian Hospital, new york, NY, 4Rheumatology, Hospital for Special Surgery; Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: antiphospholipid antibodies and transplantation, Kidney

  • Tweet
  • Email
  • Print
Session Information

Session Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antiphospholipid antibody (aPL) positive patients undergoing kidney transplantation (Tx) are at increased risk for perioperative complications. The objective of this study was to analyze the outcomes of aPL-positive patients who were managed by a risk-stratified perioperative “standard of care” protocol while undergoing kidney Tx.

Methods: We designed a “standard of care” protocol based on patient’s immunological and aPL risk profiles. Low Immunological Risk (IR) was defined as negative donor flow crossmatch (T and B cell XM) with/without donor specific antibodies; Moderate IR was defined as positive donor flow crossmatch (T and/or B cell XM) with positive donor specific antibodies; and High IR defined as was ABO incompatibility OR positive donor CDC T cell crossmatch with positive donor specific antibodies. Low aPL Risk was defined as anticardiolipin antibody (aCL) or anti-β2Glycoprotein-I (aβ2GPI) IgG/M/A 20-39U at least twice ≥ 12w apart AND negative lupus anticoagulant (LA) test; High aPL Risk was aCL/aβ2GPI IgG/M/A ≥40U OR a positive LA test twice ≥ 12w apart. We categorized patients into 6 groups and assigned different management strategies to each group (Table). For this descriptive preliminary analysis, we retrospectively reviewed the charts for perioperative and 6-month follow-up thrombosis, graft failure, and glomerular filtration rate (GFR).

Risk Stratification

Low IR

Low aPL

Low IR

High aPL

Moderate IR

Low aPL

Moderate IR

High aPL

High IR

Low aPL

High IR

High aPL

Pre-Tx Immunosuppressive

Regimen

No

No

Rituximab

MMF

Rituximab

MMF

Rituximab

MMF

 

Rituximab

MMF

 

Pre-Tx Antiplatelet/

Anticoagulation

Pre-Transplant Warfarin (+): Bridge Anticoagulation with Heparin

Pre-Transplant Warfarin (-): ASA 81 mg daily for low aPL-risk

 

Post-Tx

Immunosuppressive

Regimen

Induction Therapy*

MMF

Tacrolimus

MMF

Tacrolimus

IVIG

MMF

Tacrolimus

Prednisone

MMF

Tacrolimus

Prednisone IVIG**

MMF

Tacrolimus

Prednisone

MMF

Tacrolimus

Prednisone

IVIG**

Post Tx Antiplatelet/

Anticoagulation***

Aspirin

8-12w

UFH to Warfarin

8-12w

Aspirin

8-12w

UFH to Warfarin

8-12w

Aspirin

8-12w

UFH to Warfarin

8-12w

* Induction therapy consists in either Thymoglobulin 5 doses OR Basiliximab 2 doses AND pulse steroids for 4 days; ** The only immunosuppressive agent given for aPL-purposes; *** For patients who are not on long-term warfarin treatment. MMF: Mycophenolate Mofetil; UFH: Unfractionated Heparin.

Results: Eight patients (mean age: 49.2 ± 19.3; female: 4) underwent kidney transplantation (4 low IR/aPL risk; 2 low IR and high aPL risk; and 2 moderate IR and high aPL risk). Reasons for kidney Tx were lupus nephritis (5), polycystic kidney disease (2), and focal segmental glomerulosclerosis (1). No delayed graft function, thrombosis, or thrombotic microangiopathy were reported in the 6-month postoperative time. Median glomerular filtration rates at 30 days and 6-month post Tx were 70.65 (range 54-86) ml/min and 79.95 (range 36-112) ml/min, respectively. Median spot urine albumin-to-creatinine ratios at 30 days and 6-month post Tx were 53.3 mg/g (range 7-535) and 23.5 mg/g (range 5-244), respectively. One patient had perinephric hematoma on postoperative day one that was drained without further complications.

Conclusion: Our preliminary analysis suggests that a risk-stratified perioperative management strategy based on immunological and aPL risk profiles of aPL-positive patients undergoing kidney transplantation is safe. Future analysis of aPL-positive patients undergoing transplantation with and without risk-stratified management approach will determine if our approach improves clinical outcomes.


Disclosure:

V. Domingues,
None;

D. Dadhania,
None;

C. Hartono,
None;

R. Pastore,
None;

D. Erkan,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-risk-stratified-perioperative-management-strategy-for-antiphospholipid-antibody-positive-patients-undergoing-kidney-transplantation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies